Cancer immunotherapy is the use of the immune system to treat cancer. It uses substances either made by the body or in a laboratory to improve or restore immune system function. There are several types of cancer immunotherapies, including monoclonal antibodies, non-specific immunotherapies, oncolytic virus therapy, T-cell therapy, and cancer vaccines. FDA-approved antibodies include Alemtuzumab (Campeth-1H), Atezolizumab, Ipilimumab (Yervoy), Nivolumab, Ofatumumab, Pembrolizumab, Rituximab, etc. Besides monoclonal antibodies can be used as an immunotherapy, the PD-1/PD-L1 and CTLA-4 immune checkpoints pathways are critical to the immune system’s ability to control cancer growth. Ipilimumab (Yervoy), Nivolumab (Opdivo), and Pembrolizumab (Keytruda) are examples of immune checkpoint inhibitors. Like monoclonal antibodies, non-specific immunotherapies or cytokine therapy such as interferons – interferon alpha (Roferon-A [2a], Intron A [2b], Alferon [2a]) and interleukins – interleukin-2, IL-2, or aldesleukin (Proleukin) also help the immune system destroy cancer cells. HPV vaccine and Hepatitis B vaccine are the two cancer prevention vaccines approved by the U.S. FDA.
The global cancer immunotherapy market segmentation is based on cancer type (blood cancers, breast cancer, colorectal cancer, lung cancer, melanoma, prostate cancer, others), therapy type (cancer vaccines, immune checkpoint inhibitors – CTLA-4, PD-1/PD-L1, immune system modulators, monoclonal antibodies, others), end users (ambulatory surgical centers, cancer research centers, clinics, hospitals).
The global cancer immunotherapy market report provides market size (Revenue USD Million 2014 to 2021), market share, trends and forecasts growth trends (CAGR%, 2017 to 2021). The global cancer immunotherapy market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global cancer immunotherapy market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.
Major players operating in the global cancer immunotherapy market and profiled in this report include Amgen, Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc., Janssen Biotech, Inc., Merck & Co., Novartis AG, Pfizer, Inc., Sanofi, Spectrum Pharmaceuticals, Inc., and Takeda Pharmaceuticals.